Literature DB >> 19498025

Bortezomib and EGCG: no green tea for you?

Jatin J Shah1, Deborah J Kuhn, Robert Z Orlowski.   

Abstract

Entities:  

Year:  2009        PMID： 19498025      PMCID： PMC2700310          DOI： 10.1182/blood-2009-03-204776

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.

Authors:  Wei Zou; Ping Yue; Na Lin; Min He; Zhongmei Zhou; Sagal Lonial; Fadlo R Khuri; Binghe Wang; Shi-Yong Sun
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

2.  Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E.

Authors:  H H Chow; Y Cai; D S Alberts; I Hakim; R Dorr; F Shahi; J A Crowell; C S Yang; Y Hara
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-01       Impact factor: 4.254

3.  Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals.

Authors:  H-H Sherry Chow; Iman A Hakim; Donna R Vining; James A Crowell; James Ranger-Moore; Wade M Chew; Catherine A Celaya; Steven R Rodney; Yukihiko Hara; David S Alberts
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

4.  Catechin and caffeine content of green tea dietary supplements and correlation with antioxidant capacity.

Authors:  Navindra P Seeram; Susanne M Henning; Yantao Niu; Rupo Lee; H Samuel Scheuller; David Heber
Journal:  J Agric Food Chem       Date:  2006-03-08       Impact factor: 5.279

5.  Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer.

Authors:  Sivagurunathan Somasundaram; Natalie A Edmund; Dominic T Moore; George W Small; Yue Y Shi; Robert Z Orlowski
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

6.  Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.

Authors:  Yoshiaki Ogawa; Kensei Tobinai; Michinori Ogura; Kiyoshi Ando; Takahide Tsuchiya; Yukio Kobayashi; Takashi Watanabe; Dai Maruyama; Yasuo Morishima; Yoshitoyo Kagami; Hirofumi Taji; Hironobu Minami; Kuniaki Itoh; Masanobu Nakata; Tomomitsu Hotta
Journal:  Cancer Sci       Date:  2007-10-27       Impact factor: 6.716

7.  Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.

Authors:  Feng-Ting Liu; Samir G Agrawal; Zanyar Movasaghi; Peter B Wyatt; Ihtesham U Rehman; John G Gribben; Adrian C Newland; Li Jia
Journal:  Blood       Date:  2008-07-16       Impact factor: 22.113

8.  Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.

Authors:  Encouse B Golden; Philip Y Lam; Adel Kardosh; Kevin J Gaffney; Enrique Cadenas; Stan G Louie; Nicos A Petasis; Thomas C Chen; Axel H Schönthal
Journal:  Blood       Date:  2009-02-03       Impact factor: 22.113

9.  Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

Authors:  Christos N Papandreou; Danai D Daliani; Darrell Nix; Hong Yang; Timothy Madden; Xuemei Wang; Christine S Pien; Randall E Millikan; Shi-Ming Tu; Lance Pagliaro; Jeri Kim; Julian Adams; Peter Elliott; Dixie Esseltine; Alexandria Petrusich; Pauline Dieringer; Cherie Perez; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544
  9 in total
  7 in total

1.  Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability.

Authors:  Jun Ge; Ben-Xu Tan; Ye Chen; Li Yang; Xing-Chen Peng; Hong-Ze Li; Hong-Jun Lin; Yu Zhao; Meng Wei; Ke Cheng; Long-Hao Li; Hang Dong; Feng Gao; Jian-Ping He; Yang Wu; Meng Qiu; Ying-Lan Zhao; Jing-Mei Su; Jian-Mei Hou; Ji-Yan Liu
Journal:  J Mol Med (Berl)       Date:  2011-02-18       Impact factor: 4.599

Review 2.  Natural compounds as anticancer agents: Experimental evidence.

Authors:  Jiao Wang; Yang-Fu Jiang
Journal:  World J Exp Med       Date:  2012-06-20

Review 3.  Proteasome inhibitors in the treatment of multiple myeloma.

Authors:  J J Shah; R Z Orlowski
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

4.  Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.

Authors:  Bret Bannerman; Ling Xu; Matthew Jones; Christopher Tsu; Jie Yu; Paul Hales; Johan Monbaliu; Paul Fleming; Lawrence Dick; Mark Manfredi; Christopher Claiborne; Joseph Bolen; Erik Kupperman; Allison Berger
Journal:  Cancer Chemother Pharmacol       Date:  2011-03-13       Impact factor: 3.333

Review 5.  Key factors which concur to the correct therapeutic evaluation of herbal products in free radical-induced diseases.

Authors:  Cesare Mancuso
Journal:  Front Pharmacol       Date:  2015-04-22       Impact factor: 5.810

Review 6.  Why bortezomib cannot go with 'green'?

Authors:  Li Jia; Feng-Ting Liu
Journal:  Cancer Biol Med       Date:  2013-12       Impact factor: 4.248

7.  Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements.

Authors:  Clemens P J G Wolf; Tobias Rachow; Thomas Ernst; Andreas Hochhaus; Bijan Zomorodbakhsch; Susan Foller; Matthias Rengsberger; Michael Hartmann; Jutta Hübner
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-17       Impact factor: 4.553
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.